INmune Bio Inc. - Common stock (INMB)

Management outlined a revised UK submission strategy and early named patient access plans for Ebstracel.

Management to host conference call and webcast at 4:30 pm ET on that day

BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering of an aggregate of 3,000,000 shares of common stock and a concurrent private placement of unregistered warrants to purchase up to 3,000,000 shares common stock (together, the “Offering”). The gross proceeds to the Company from the Offering are expected to be approximately $4.50 million, before deducting placement agent fees and other estimated offering expenses. The warrants will have an exercise price of $1.65, will be exercisable six months following their issuance and will expire five and a half (5.5) years from the issuance date.

BOCA RATON, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has updated its regulatory submission strategy, as faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

Initial focus on named-patient access in selected European and MENA markets, providing a capital-efficient foundation for broader commercialization

BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease and other disease conditions.

BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET)

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity

Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.

INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027. Ch

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million.  This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026.  After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter.  The rebates strengthen the Company's balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™) toward regulatory filings.

Management to host conference call and webcast at 4:30 pm ET on that day

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.

The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom

BOCA RATON, Fla, June 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization Application (pre-MAA) Scientific Advice meeting with the UK Medicines & Healthcare products Regulatory Agency (MHRA) for CORDStrom™ (Ebstrocel™) in Recessive Dystrophic Epidermolysis Bullosa (RDEB).

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.

INmune Bio (INMB) Q4 2025 Earnings Transcript

Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer’s disease characterized by biomarkers of inflammation. In a pre-specified analysis of the protocol-defined Alzheimer’s Disease with inflammation (ADi) subgroup, XPro™ showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks, with no amyloid-related imaging abnormalities (ARIA) observed.